Biocon Biologics, the subsidiary of Biocon Ltd , has strengthened its presence in the US insulin market through a multi-year partnership with non-profit company Civica. The agreement will create an exclusive distribution channel to supply affordable insulins and other pharmaceutical products across the country.

Speaking to CNBC-TV18, Biocon Biologics CEO and MD Shreehas Tambe called the tie-up “a very significant development—not just for Biocon, but also in terms of how insulins will be made available to patients in the United States.” He highlighted that the partnership reflects the company’s robust commercial platform, which can deliver medicines through multiple channels, from hospital networks to direct consumer distribution.

Under the deal, Biocon Biologics will manufacture and su

See Full Page